Table 1.
Clinical and pathological features of GC cancer patients (n = 162).
| Clinical feature | Overall (n = 162) | Death (n = 25) | P value | Recurrence (n = 31) | P value |
|---|---|---|---|---|---|
| Sex | P = 0.678 | P = 0.510 | |||
| Male | 105 (65%) | 16 (64%) | 19 (61%) | ||
| Female | 57 (35%) | 9 (26%) | 12 (39%) | ||
| Age | P = 0.193 | P = 0.875 | |||
| ≤55 | 42 (26%) | 4 (16%) | 8 (26%) | ||
| >55 | 120 (74%) | 21 (84%) | 23 (74%) | ||
| Family historya | P = 0.048∗ | P = 0.310 | |||
| Absent | 147 (91%) | 25 (100%) | 29 (94%) | ||
| Present | 15 (9%) | 0 (0%) | 2 (6%) | ||
| Number of tumor | P = 0.117 | P = 0.253 | |||
| Single | 153 (94%) | 22 (88%) | 28 (90%) | ||
| Multiple | 9 (6%) | 3 (12%) | 3 (10%) | ||
| Nerve invasion | P = 0.080 | P = 0.010∗ | |||
| Negative | 117 (72%) | 14 (56%) | 16 (52%) | ||
| Positive | 45 (28%) | 11 (44%) | 15 (48%) | ||
| Vascular tumor thrombus | P < 0.001∗ | P < 0.001∗ | |||
| Negative | 101 (62%) | 8 (32%) | 11 (35%) | ||
| Positive | 61 (38%) | 17 (78%) | 20 (65%) | ||
| Surgical approach | P = 0.887 | P = 0.900 | |||
| Laparotomy | 143 (88%) | 22 (88%) | 28 (90%) | ||
| Laparoscopy | 19 (12%) | 3 (12%) | 3 (10%) | ||
| Clinical stageb | P < 0.001∗ | P < 0.001∗ | |||
| Stage I | 35 (22%) | 2 (8%) | 2 (6%) | ||
| Stage II | 70 (43%) | 3 (12%) | 4 (13%) | ||
| Stage III | 49 (30%) | 16 (64%) | 20 (65%) | ||
| Stage IV | 8 (5%) | 4 (16%) | 5 (16%) | ||
| Number of LNc | P < 0.001∗ | P < 0.001∗ | |||
| ≤6 | 103 (64%) | 13 (52%) | 15 (48%) | ||
| >6 | 59 (36%) | 12 (48%) | 16 (52%) | ||
| Tumor size | P = 0.649 | P = 0.686 | |||
| ≤5 cm | 103 (64%) | 14 (56%) | 18 (58%) | ||
| >5 cm | 59 (36%) | 11 (44%) | 13 (42%) | ||
| Tumor location | P = 0.138 | P = 0.352 | |||
| Cardia | 40 (25%) | 12 (48%) | 13 (42%) | ||
| Antrum | 79 (49%) | 8 (32%) | 12 (39%) | ||
| Body | 31 (19%) | 5 (20%) | 5 (16%) | ||
| Fundus | 2 (1%) | 0 (0%) | 0 (0%) | ||
| Pylorus | 1 (0%) | 0 (0%) | 0 (0%) | ||
| Angle | 9 (6%) | 0 (0%) | 1 (3%) | ||
| Degree of differentiation | P = 0.648 | P = 0.730 | |||
| Poor | 55 (34%) | 10 (40%) | 10 (32%) | ||
| Mediate | 48 (30%) | 7 (28%) | 8 (26%) | ||
| Poor-med | 55 (34%) | 8 (32%) | 12 (39%) | ||
| N/Ad | 4 (2%) | 0 (0%) | 1 (3%) | ||
| Lauren classification | P = 0.780 | P = 0.495 | |||
| Intestinal | 51 (31%) | 6 (24%) | 7 (23%) | ||
| Diffuse | 34 (21%) | 6 (24%) | 8 (26%) | ||
| Mixed | 55 (34%) | 9 (36%) | 12 (39%) | ||
| N/A | 22 (14%) | 4 (16%) | 4 (13%) | ||
| HER2 | P = 0.025∗ | P = 0.064 | |||
| 3+ | 2 (1%) | 1 (4%) | 1 (3%) | ||
| 0/1+/2+ | 156 (96%) | 23 (92%) | 29 (94%) | ||
| N/A | 4 (2%) | 1 (4%) | 1 (3%) | ||
| dMMRe | P = 0.801 | P = 0.512 | |||
| MLH1 | 6 (4%) | 2 (8%) | 3 (10%) | ||
| PMS2 | 44 (27%) | 10 (40%) | 11 (35%) | ||
| MSH2 | 4 (2%) | 0 (0%) | 0 (0%) | ||
| MSH6 | 9 (6%) | 2 (8%) | 3 (10%) | ||
| MLH1+PMS2 | 93 (57%) | 10 (40%) | 13 (42%) | ||
| MSH2+MSH6 | 5 (3%) | 1 (4%) | 1 (3%) | ||
| PMS2+MSH2+MSH6 | 1 (1%) | 0 (0%) | 0 (0%) | ||
| Treatment pattern | P = 0.487 | P = 0.215 | |||
| Surgery alone | 84 (52%) | 14 (56%) | 16 (52%) | ||
| Neoadjuvant chemotherapy | 14 (9%) | 4 (16%) | 6 (19%) | ||
| Postoperative adjuvant chemotherapy | 61 (38%) | 7 (28%) | 9 (29%) | ||
| Postoperative immunotherapy | 2 (1%) | 0 (0%) | 0 (0%) | ||
| Postoperative chemoradiotherapy | 1 (0%) | 0 (0%) | 0 (0%) |
aHistory of tumorigenic first- and second-degree relatives. bTNM staging classified according to the Union for International Cancer Control (UICC) TNM classification, 8th edition. For patients with multiple lesions, T staging was performed for the lesion with the highest T stage. cThe number of regional lymph nodes with metastases identified during surgery. dN/A indicates either that testing was not done or that the results could not be evaluated. edMMR status based on the IHC staining of MMR proteins and the loss of any MMR proteins.